Health-Related Quality of Life and Multidimensional Fatigue Scale in Children with Primary Immunodeficiencies

  • 1.

    McCusker C, Upton J, Warrington R. Primary immunodeficiency. Allergy Asthma Clin Immunol. 2018;14(2):61.

  • 2.

    Aghamohammadi A, Montazeri A, Abolhassani H, Saroukhani S, Pourjabbar S, Tavassoli M, et al. Health-related quality of life in primary antibody deficiency. Iran J Allergy Asthma Immunol. 2011;10(1):47–51.

  • 3.

    Tcheurekdjian H, Palermo T, Hosstoffer R. Quality of life in common variable immunodeficiency requiring intravenous. Ann Allergy Asthma Immunol. 2004;93(2):160–5.

  • 4.

    Zebracki K, Palermo TM, Hostoffer R, Duff K, Drotar D. Health-related quality of life of children with primary immunodeficiency disease: a comparison study. Ann Allergy Asthma Immunol. 2004;93:557–61.

  • 5.

    Mozaffari H, Pourpak Z, Pourseyed S, Moin M, Farhoodi A, Aghamohammadi A, et al. Health-related quality of life in primary immune deficient patients. Iran J Allergy Asthma Immunol. 2006;5(1):23–7.

  • 6.

    Lavigne J, Fair-Rotman J. Psychological adjustment to pediatric physical disorders: a meta-analytic review. J Pediatr Psychol. 1992;17(2):133–57.

  • 7.

    Kuburovic NB, Pasic S, Susic G, Stevanovic D, Kuburovic V, Zdravkovic S, et al. Health-related quality of life, anxiety, and depressive symptoms in children with primary immunodeficiencies. Patient Prefer Adherence. 2014;8:323–30.

  • 8.

    Abolhassani H, Aghamohammadi A, Abolhassani F, et al. Health policy for common variable immunodeficiency: burden of the disease. J Invest Allergol Clin Immunol. 2011;21(6):454–8.

  • 9.

    Sadeghi B, Abolhassani H, Naseri A, et al. Economic burden of common variable immunodeficiency: annual cost of disease. Exp Rev Clin Immunol. 2015;11(5):681–8.

  • 10.

    Mathew F, Steven D, Janine D, Stephen B. What are quality of life measurements measuring? BMJ. 1993;316(7130):542–54.

  • 11.

    Eiserc C, Morse R. The measurement of quality of life in children: past and future perspectives. J Dev Behav Pediatr. 2001;22(4):248–56.

  • 12.

    Ataeinia B, Montazeri A, Tavakol M, Azizi G, Kiaee F, Tavakolinia N, et al. Measurement of health-related quality of life in primary antibody-deficient patients. Immunol Invest. 2017. https://doi.org/10.1080/08820139.2016.1258710.

  • 13.

    Barlogis V, Mahlaoui N, Auquier P, Pellier I, Fouyssac F, Vercasson C, et al. Physical health conditions and quality of life in adults with primary immune deficiency diagnosed during childhood: a CEREDIH study. J Allergy Clin Immunol. 2016;139(4):1275–81.

  • 14.

    Routes J, Tavares-Costa-Carvalho B, Grimbacher B, Paris K, Ochs HD, Filipovich A, et al. Health-related quality of life and health resource utilization in patients with primary immunodeficiency disease prior to and following 12 months of immunoglobulin G treatment. J Clin Immunol. 2016;36:450–61.

  • 15.

    Jiang F, Torgerson TR, Ayars AG. Health-related quality of life in patients with primary immunodeficiency disease. Allergy Asthma Clinical Immunol. 2015. https://doi.org/10.1186/s13223-015-0092-y.

  • 16.

    Titman P, Allwood Z, Gilmour C, Malcolmson C, Duran-Persson C, Cale C, et al. Quality of life in children with primary antibody deficiency. J Clin Immunol. 2014;34:844–85.

  • 17.

    Piazza-Waggoner C, Adams CD, Cottrell L, Taylor BK, Wilson NW, Hogan MB. Child and caregiver psychosocial functioning in pediatric immunodeficiency diseases. Ann Allergy Asthma Immunol. 2006;96:298–303.

  • 18.

    Peshko D, Kulbachinskaya E, Korsunsky I, Kondrikova E, Pulvirenti F, Quinti I, et al. Health-related quality of life in children and adults with primary immunodeficiencies: a systematic review and meta-analysis. J Allergy Clin Imm Pract. 2019;7(6):1929–1957.e5.

  • 19.

    Español T, Prevot J, Drabwell J, Sondhi S, Olding L. Improving current immunoglobulin therapy for patients with primary immunodeficiency: quality of life and views on treatment. Patient Prefer Adherence. 2014;8:621–9.

  • 20.

    Berger M, Murphy E, Riley P, Bergman GE. Improved quality of life, immunoglobulin G levels, and infection rates in patients with primary immunodeficiency diseases during self-treatment with subcutaneous immunoglobulin G. South Med J. 2010;103(9):856–63.

  • 21.

    Fasth A, Nyström J. Quality of life and health-care resource utilization among children with primary immunodeficiency receiving home treatment with subcutaneous human immunoglobulin. J Clin Immunol. 2008;28:370–8.

  • 22.

    Gardulf A, Nicolay U, Math D, Asensio O, Bernatowska E, Böck A, et al. Children and adults with primary antibody deficiencies gain quality of life by subcutaneous IgG self-infusions at home. J Allergy Clin Immunol. 2004;114:936–42.

  • 23.

    Heath J, Lehman E, Saunders EF, Craig T. Anxiety and depression in adults with primary immunodeficiency: how much do these patients experience and how much do they attribute to their primary immunodeficiency? Allergy Asthma Proc. 2016;37(5):409–15.

  • 24.

    Sultan S, Rondeau E, Levasseur MC, Dicaire R, Decaluwe H, Haddad E. Quality of life, treatment beliefs, and treatment satisfaction in children treated for primary immunodeficiency with SCIg. J Clin Immunol. 2017;37(5):496–504.

  • 25.

    Cole T, McKendrick F, Titman P, Cant AJ, Pearce MS, Cale CM, et al. Health related quality of life and emotional health in children with chronic granulomatous disease: a comparison of those managed conservatively with those that have undergone haematopoietic stem cell transplant. J Clin Immunol. 2013;33(1):8–13.

  • 26.

    Heimall J, Puck J, Buckley R, Fleisher TA, Gennery AR, Neven B, et al. Current knowledge and priorities for future research in late effects after hematopoietic stem cell transplantation (HCT) for severe combined immunodeficiency patients: a consensus statement from the second pediatric blood and marrow transplant consortium international conference on late effects after pediatric HCT. Biol Blood Marrow Transplant. 2017;23:379–87.

  • 27.

    Picard C, Gaspar HB, Al-Herz W, Bousfiha A, Casanova JL, Chatila T, et al. International Union of Immunological Societies: 2017 primary immunodeficency diseases committee report on inborn errors of immunity. J Clin Immunol. 2018;38(1):96–128.

  • 28.

    Varni JW, Limbers CA, Burwinkle TM. Impaired health-related quality of life in children and adolescents with chronic conditions: a comparative analysis of 10 disease clusters and 33 disease categories/severities utilizing the PedsQL 4.0 Generic Core Scales. Health Qual Life Outcomes. 2007;5:43.

  • 29.

    Varni JW, Burwinkle TM, Seid M, Skarr D. The PedsQL™ 4.0 as a pediatric population health measure: feasibility, reliability, and validity. Ambul Pediatr. 2003;3(6):329–41.

  • 30.

    Gordijn MS, Cremers E, Kaspers G, Gemke R. Fatigue in children: reliability and validity of the Dutch PedsQL™ Multidimensional Fatigue Scale. Qual Life Res. 2011;20:1103–8.

  • 31.

    Crichton A, Knight S, Oakley E, Babl FE, Anderson V. Fatigue in child chronic health conditions: a systematic review of assessment instruments. Pediatrics. 2015;135(4):e1015–31.

  • 32.

    Oken M, Creech R, Tormey D, Horton J, Davis TE, McFadden E, et al. Toxicity and response criteria of the eastern cooperative oncology group. Am J Clin Oncol. 1982;5:649–55.

  • 33.

    Departament de Treball, Afers socials i Famílies. What is dependency and how is it recognized?. In: Generalitat de Catalunya. 2014. Available at: http://treballiaferssocials.gencat.cat/ca/ambits_tematics/persones_amb_dependencia/que_es_i_com_es_reconeix_la_situacio_de_dependencia/. Last accessed 10 Jul 2019.

  • 34.

    Nap-van der Vlist MM, Dalmeijer GW, Grootenhuis MA, Van der Ent CK, Van den Heuvel-Eibrink MM, Wulffraat NM, et al. Fatigue in childhood chronic disease. Arch Dis Child. 2019;104:1090–5.

  • 35.

    Hajjar J, Guffey D, Minard CG, Orange JS. Increased incidence of fatigue in patients with primary immunodeficiency disorders: prevalence and associations within the US immunodeficiency network registry. J Clin Immunol. 2017;37(2):153–65.

  • 36.

    Rojavin MA, Hubsch A, Lawo JP. Quantitative evidence of wear-off effect at the end of the intravenous IgG (IVIG) dosing cycle in primary immunodeficiency. J Clin Immunol. 2016;36(3):210–9.

  • This content is also available in: English Español

    Do NOT follow this link or you will be banned from the site!